Several studies demonstrate endogenous androgen excess in adult trans male patients, but data are lacking in adolescents. Identifying hyperandrogenism in growing children is relevant, as it can be the first sign of serious adrenal conditions and can be associated with advanced skeletal maturity and premature growth cessation. We sought to identify the percentage of adolescent trans male patients who, prior to gender affirming treatment, had biochemical hyperandrogenism relative to reference ranges and to a comparison group.
Methods:
We conducted a retrospective chart review of patients seen between 2013 and 2020 at an academic pediatric center with a multidisciplinary gender team. Participants included 177 trans male patients and 166 cisgender female patients who underwent endocrine evaluation and 11 trans males and 15 cisgender females who completed adrenocorticotropic hormone (ACTH) stimulation tests for hyperandrogenism. We analyzed differences in androgen levels, bone ages, and adult heights.
Results:
Eighty-eight of 172 (51.2%) trans males tested exhibited elevations of one or more androgens compared to 24/158 (15.2%) cisgender females (p < 0.0001). Trans males were more likely than cisgender females to have elevated dehydroepiandrostenedione (DHEA) (p = 0.0056) and dehydroepiandrostenedione sulfate (p = 0.0005) levels compared to age-adjusted reference ranges. Trans males displayed significantly higher DHEA responses to ACTH (p = 0.019), more advanced bone ages (p = 0.00014), and lower median adult height (p = 0.001) compared to cisgender females.
Conclusions:
A higher percentage of trans male patients had elevated levels of adrenal steroids, more advanced bone ages, and lower median adult heights compared to cisgender females.
BalenAH, SchachterME, MontgomeryD, et al.Polycystic ovaries are a common finding in untreated female to male transsexuals. Clin Endocrinol (Oxf), 1993; 38(3):325–329; doi: 10.1111/j.1365-2265.1993.tb01013.x
2.
BabaT, EndoT, HonnmaH, et al.Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod, 2007; 22(4):1011–1016; doi: 10.1093/humrep/del474
3.
BabaT, EndoT, IkedaK, et al.Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in Japan. J Sex Med, 2011; 8(6):1686–1693; doi: 10.1111/j.1743-6109.2011.02252.x
4.
Becerra-FernándezA, Pérez-LópezG, RománMM, et al.Prevalence of hyperandrogenism and polycystic ovary syndrome in female to male transsexuals. Endocrinol Nutr, 2014; 61(7):351–358; doi: 10.1016/j.endonu.2014.01.010
5.
BosinskiHA, PeterM, BonatzG, et al.A higher rate of hyperandrogenic disorders in female-to-male transsexuals. Psychoneuroendocrinology, 1997; 22(5):361–380; doi: 10.1016/s0306-4530(97)00033-4
6.
BosinskiHA, SchröderI, PeterM, et al.Anthropometrical measurements and androgen levels in males, females, and hormonally untreated female-to-male transsexuals. Arch Sex Behav, 1997; 26(2):143–157; doi: 10.1023/a:1024506427497
7.
Kvernebo SunnergrenK, Ankarberg-LindgrenC, DahlgrenJ. Adrenal and gonadal activity, androgen concentrations, and adult height outcomes in boys with Silver-Russell syndrome. Front Endocrinol (Lausanne), 2019; 10:829; doi: 10.3389/fendo.2019.00829
8.
YoungMC, RibeiroJ, HughesIA. Growth and body proportions in congenital adrenal hyperplasia. Arch Dis Child, 1989; 64(11):1554–1558; doi: 10.1136/adc.64.11.1554
9.
WasniewskaMG, MorabitoLA, BaronioF, et al.Adrenal Diseases Working Group of the Italian Society for Pediatric Endocrinology and Diabetology. Growth trajectory and adult height in children with nonclassical congenital adrenal hyperplasia. Horm Res Paediatr, 2020; 93(3):173–181; doi: 10.1159/000509548
10.
American Medical Association. ICD-10-CM 2022 the Complete Official Codebook with Guidelines. American Medical Association: Chicago, IL; 2021.
11.
Practice Management Information Corporation. ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification, 5th Edition. Practice Management Information Corporation: Los Angeles, CA; 1999.
12.
GrimstadFW, KnollMM, JacobsonJD. Oxandrolone use in trans-masculine youth appears to increase adult height: Preliminary evidence. LGBT Health, 2021; 8(4):300–306; doi: 10.1089/lgbt.2020.0355
13.
TeedeHJ, MissoML, CostelloMF, et al.International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod, 2018; 33(9):1602–1618; doi: 10.1093/humrep/dey256
14.
ElmlingerMW, KühnelW, RankeMB. Reference ranges for serum concentrations of lutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and young adults. Clin Chem Lab Med, 2002; 40(11):1151–1160; doi: 10.1515/CCLM.2002.202
15.
TannerJM, GoldsteinH, WhitehouseRH. Standards for children’s height at age 2 to 9 years allowing for height of parents. Arch Dis Child, 1970; 45(244):819; doi: 10.1136/adc.45.244.819-b
16.
PyleSI, WaterhouseAM, GreulichWW. Attributes of the radiographic standard of reference for the National Health Examination Survey. Am J Phys Anthropol, 1971; 35(3):331–337; doi: 10.1002/ajpa.1330350306
17.
BayleyN, PinneauSR. Tables for predicting adult height from skeletal age: Revised for use with the greulich-pyle hand standards. J Pediatr, 1952; 40(4):423–441; doi: 10.1016/S0022-3476(52)80205-7
18.
OlsonJ, SchragerSM, BelzerM, et al.Baseline physiologic and psychosocial characteristics of transgender youth seeking care for gender dysphoria. J Adolesc Health, 2015; 57(4):374–380; doi: 10.1016/j.jadohealth.2015.04.027
19.
HembreeWC, Cohen-KettenisPT, GoorenL, et al.Endocrine treatment of gender-dysphoric/gender-incongruent persons: An endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2017; 102(11):3869–3903; doi: 10.1210/jc.2017-01658
20.
WrightT, CandyB, KingM. Conversion therapies and access to transition-related healthcare in transgender people: A narrative systematic review. BMJ Open, 2018; 8(12):e022425; doi: 10.1136/bmjopen-2018-022425
21.
RandhawaH, KnollMM, McPhaulM, et al.Prevalence of intersex/differences in sex development and primary gonadal insufficiency in a pediatric transgender population. Transgender Health, 2023; doi: 10.1089/trgh.2023.0033
22.
DutheilF, de Saint VincentS, PereiraB, et al.DHEA as a biomarker of stress: A systematic review and meta-analysis. Front Psychiatry, 2021; 12:688367; doi: 10.3389/fpsyt.2021.688367
23.
LamJCW, ShieldsGS, TrainorBC, et al.Greater lifetime stress exposure predicts blunted cortisol but heightened DHEA responses to acute stress. Stress Health, 2019; 35(1):15–26; doi: 10.1002/smi.2835
24.
SöndergaardHP, HanssonL-O, TheorellT. Elevated blood levels of dehydroepiandrosterone sulphate vary with symptom load in posttraumatic stress disorder: Findings from a longitudinal study of refugees in Sweden. Psychother Psychosom, 2002; 71(5):298–303; doi: 10.1159/000064806
25.
YehudaR, BrandSR, GolierJA, et al.Clinical correlates of DHEA associated with post-traumatic stress disorder. Acta Psychiatr Scand, 2006; 114(3):187–193; doi: 10.1111/j.1600-0447.2006.00801.x
26.
Van VoorheesEE, DennisMF, CalhounPS, et al.Association of DHEA, DHEAS, and cortisol with childhood trauma exposure and post-traumatic stress disorder. Int Clin Psychopharmacol, 2014; 29(1):56–62; doi: 10.1097/YIC.0b013e328364ecd1
27.
HaglundMEM, NestadtPS, CooperNS, et al.Psychobiological mechanisms of resilience: Relevance to prevention and treatment of stress-related psychopathology. Dev Psychopathol, 2007; 19(3):889–920; doi: 10.1017/S0954579407000430
28.
SopherAB, JeanAM, ZwanySK, et al.Bone age advancement in prepubertal children with obesity and premature adrenarche: Possible potentiating factors. Obesity (Silver Spring), 2011; 19(6):1259–1264; doi: 10.1038/oby.2010.305
29.
KwonJH, LeeHA, KimYJ, et al.Effects of adrenal androgen levels on bone age advancement in prepubertal children: Using the ewha birth and growth cohort study. J Korean Med Sci, 2017; 32(6):968–973; doi: 10.3346/jkms.2017.32.6.968
30.
HucklebridgeF, HussainT, EvansP, et al.The diurnal patterns of the adrenal steroids cortisol and dehydroepiandrosterone (DHEA) in relation to awakening. Psychoneuroendocrinology, 2005; 30(1):51–57; doi: 10.1016/j.psyneuen.2004.04.007
31.
CharoensriS, ChailurkitL, MunthamD, et al.Serum dehydroepiandrosterone sulfate in assessing the integrity of the hypothalamic-pituitary-adrenal axis. J Clin Transl Endocrinol, 2017; 7:42–46; doi: 10.1016/j.jcte.2017.01.001
32.
HamidovicA, SoumareF, NaveedA, et al.Reduced dehydroepiandrosterone-sulfate levels in the mid-luteal subphase of the menstrual cycle: Implications to women’s health research. Metabolites, 2022; 12(10):941; doi: 10.3390/metabo12100941
33.
SequeiraGM, RayKN, MillerE, et al.Transgender youth’s disclosure of gender identity to providers outside of specialized gender centers. J Adolesc Health, 2020; 66(6):691–698; doi: 10.1016/j.jadohealth.2019.12.010
34.
NazMSG, TehraniFR, MajdHA, et al.The prevalence of polycystic ovary syndrome in adolescents: A systematic review and meta-analysis. Int J Reprod Biomed, 2019; 17(8):533–542; doi: 10.18502/ijrm.v17i8.4818
